Completion of 10 Trillion Won Acquisition of Clinical Data Company.. Enhancing Bio Clinical 'Big Data'

Thermo Fisher Scientific Inc. (TMO) announced on March 24 that it has completed its acquisition of clinical-trial endpoint data solutions provider Clario Holdings for approximately $8.875 billion. The purchase price consists of cash, amounts payable in January 2027, and up to $400 million of performance-based consideration tied to 2026–2027 results. Clario will be folded into Thermo Fisher’s Lab Products & Biopharma Services segment, enhancing the company’s clinical-research and data-intelligence capabilities. Thermo Fisher expects the transaction to deliver a double-digit internal rate of return, drive mid-to-high single-digit revenue growth at Clario, improve adjusted operating margin and EPS, and generate about $175 million of synergies within five years.

Separately, Chairman and CEO Mark N. Casper, under a pre-established Rule 10b5-1 trading plan, exercised stock options and sold a portion of the resulting shares from March 3–5, realizing proceeds in the millions of dollars, while maintaining direct ownership of roughly $60 million of equity.

Alongside its full-year 2025 results announced at the end of January, Thermo Fisher reaffirmed its 2026 guidance of $46.3–47.2 billion in revenue and $24.22–24.80 in adjusted EPS, forecasting that the Clario acquisition will boost this year’s adjusted EPS by approximately $0.20–0.25. To fund the acquisition, the company issued $3.8 billion of senior notes in February for acquisition and general corporate purposes. In March, Thermo Fisher also expanded its clinical-development services—particularly in oncology—by partnering with AIM ImmunoTech on a Phase III cancer trial.

Thermo Fisher is a leading U.S. provider of life-science research instruments, reagents, analytical and diagnostic systems, clinical-development solutions, and contract development and manufacturing services. As global pharma and biotech companies increasingly outsource clinical trials and data analytics to streamline drug development, the CRO, clinical-data, and digital-clinical-platform sectors have emerged as structurally growing industries attracting significant bio-healthcare investment.